诊断技术

2020年7月13日

揭示IDTechEx新闻分享这篇文章提供的波士顿,7月13日,2020而从COVID-19疫情继续上升在一些国家,很多人已经成功地降低了日常新病例和繁殖的数字。欧洲国家已经放松一般锁定,如德国、西班牙和英国。一起去检疫是巨大的每日COVID-19测试数据。图:一些COVID-19 POC MDx设备的诊断。更多细节可以发现IDTechEx报告,“COVID-19诊断”。图:各种血清学测试设备。IDTechEx预测增长的市场为高敏感性和特异性免疫测定设备正在成为占主导地位的考虑。更多细节可以发现IDTechEx报告,“COVID-19诊断”。来源:www.IDTechEx.com/COVID IDTechEx (PRNewsfoto / IDTechEx)相反,测试仍然是一个最有力的措施来控制新的暴发。在本文中,我们展示了COVID-19诊断的重点从大规模测试转移到更有效的测量和快速响应。 This will bring about a change in the type of diagnostic technologies used. Find a detailed comparison of different COVID-19 diagnostics technologies in the IDTechEx report " COVID-19 Diagnostics ", from the perspective of technique advancement, performance, cost, availability and key suppliers. The virus will be still among us for the long term in the absence of a vaccine. To prevent future large outbreaks and a second wave of national lockdown, early and quick diagnostics will become essential. Instead of massive testing, contact tracing and confinement of local outbreaks will be needed. In this way, testing methods that do not require extensive central lab equipment and that can be deployed at community settings will be more prominent in the market. Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) is the technology that has dominated and will continue to dominate the COVID-19 testing market in the outbreak due to its high reliability and large throughput. However, the centralised setting leads to long sample-to-answer time (24 hours to 6 days), mainly due to logistic problems and long testing time. This disadvantage is becoming a bottleneck in the new phase of COVID-19 testing. This sets the scene for the growth of point-of-care molecular diagnostics (POC MDx) devices such as Abbott's ID now and Cepheid. In less than 30 minutes, the genetic material found in a sample can be amplified and detected in a printer-sized device. POC MDx is a premium solution to provide fast testing to new outbreaks and support a swift response to confine the spread of coronavirus. Although these POC technologies have lower sensitivity and specificity than the gold standard RT-qPCR, they prove a valuable resource in surveillance testing in the post-quarantine time. " COVID-19 Diagnostics ", identifies key innovations and technology trends currently being developed in the diagnostics ecosystem that will enable quick and sensitive diagnosis of COVID-19 at point-of-care settings. Another trend IDTechEx predicts is the fast adoption of Serological tests, which indicate the presence of antibodies against the virus. Serological tests are of importance for assessing the severity of outbreaks and obtaining valuable epidemiological data. Rapid lateral flow assays (LFAs) that resemble "pregnancy tests" have had issues of low sensitivity and specificity. As the pandemic gets under control, the demand for more accurate serological test will be higher. In this context, accurate immunoassays, such as ELISA or chemoimmunoassay, will be more relevant as opposed to traditional lateral flow assays. Although many of them will require large equipment or even a laboratory setting, high sensitivity and specificity will be the key driver for the adoption. We have seen a faster than expected development of diagnostics technologies, such as CRISPR based POC MDx, DNA sequencing as diagnostics protocol and a hybrid system combining amplification with various detection methods. The transfer of technology from R&D to commercial devices has been accelerated from years to only a couple of months. The IDTechEx report, " COVID-19 Diagnostics ", provides a comprehensive analysis of and deep insights into the technology evolution. Furthermore, this report highlights the bottleneck for the testing and identifies the promising technologies for the years to come. For more information on this report, please visit www.IDTechEx.com/COVID or for the full portfolio of research available from IDTechEx please visit www.IDTechEx.com/Research . IDTechEx guides your strategic business decisions through its Research, Consultancy and Event products, helping you profit from emerging technologies. For more information on IDTechEx Research and Consultancy, contact [email protected] or visit www.IDTechEx.com . Media Contact: